Aristotle University Of Thessaloniki (AUTH)
Αξιολόγηση της θεραπείας με πλούσιο σε αιμοπετάλια πλάσμα στη στυτική δυσλειτουργία
Abstract
dc:descriptionBackground: Animal studies postulate that platelet-rich plasma (PRP) injections improve key elements of the pathophysiologic mechanisms leading to erectile dysfunction (ED). Aim: To conduct the first double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of PRP injections in patients with mild and moderate ED. Methods: Sixty sexually active patients with mild and moderate ED were randomly assigned to two sessions, with a one-month difference, of 10 mL PRP (n = 30) or placebo (n = 30) intracavernosal injections. An FDA-approved separation system was used. Patients were evaluated at 1, 3 and 6 months after completion of the treatment protocol. A per-protocol analysis was applied. All participants withheld any ED treatment during the trial. Outcomes: The achievement of minimal clinically important difference (MCID) in the International Index of Erectile Function -Erectile Domain (IIEF-EF) from baseline to 6 months after final treatment. Erectile function at all time points, as well as safety of PRP injections, were also evaluated. Results: At 6 months, a MCID was achieved by 20/29 (69%) patients in the PRP group compared to 7/26 (27%) in the placebo group. The risk difference between the two groups was 42% (95%CI: 18-66), P < 0.001 and the baseline-adjusted mean between-group-difference in the IIEF-EF score was 3.9 points (95%CI: 1.8-5.9). Similarly, a statistically significant difference of both the number of participants attaining a MCID and the IIEF-EF score was also observed at the 1- and 3-month evaluation between the two groups. Accordingly, patients receiving PRP were more satisfied with the treatment. No adverse events were observed during the study period. Clinical implications: Intracavernosal PRP injection therapy used as outlined in this trial appears to be a safe and effective short-term treatment for the management of mild to moderate ED. Strengths & Limitations: We conducted the first clinical trial exploring the role of PRP in the management of ED. Conversely, our findings lack external validity due to single-center design. Furthermore, our results cannot be extrapolated to other PRP separation systems. Conclusions: PRP intracavernosal injections may be a promising addition to the urologist’s armamentarium for the management of ED. Still, further high-quality studies are warranted to corroborate our findings.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Poulios, Evangelos
- Πούλιος, Ευάγγελος
Subjects
dc:subject × 15- Πλάσμα πλούσιο σε αιμοπετάλια (PRP)
- Στυτική λειτουργία
- Στυτική δυσλειτουργία
- Τυχαιοποιημένες ελεγχόμενες δοκιμές
- Platelet-rich plasma
- PRP
- Erectile function
- Erectile dysfunction
- randomized controlled trial
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ανδρολογία
- Clinical Medicine
- Medical and Health Sciences
- Andrology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/54741